We could have banked $20M 3 years ago!
Instead we are diluted down to 2.3% from 2.8%.
Trading update should be out next week that should remind people of the massive discount on offer.
Really need some hard info on Glycotest which should be close to a final read out.
Charles is doing the investor rounds this month so you assume he has something to sell. |
You have to wonder what we are paying our BOD for?
Certainly not their investment skills!
Zero return on our investment over 5 years.
They could have banked $20M on this at the end of the covid excess 3 years ago.
Holding worth less than $2M now!
Unfortunately, we are faced with being diluted to oblivion or using a chunk of our placing cash to keep in the game. |
And they got their cash raise underway ..thia is really good news IMV. |
PDS results are pretty good! |
 SageTech Medical is pleased to announce a significant advancement in its mission to lead sustainable anaesthesia. The company has signed a distribution agreement with the Dräger Schweiz AG, a medical device manufacturer and distributor known for its innovative anaesthesia delivery systems. This collaboration will enhance SageTech Medical’s footprint in Europe and support its growth strategy.
The agreement represents a key step in the European commercialisation of SageTech Medical’s SID-Dock, an innovative Class 1 medical device designed to safely and sustainably capture waste anaesthetic gases. The SID-Dock not only supports compliance with recent EU F-Gas legislation but also aligns with the healthcare sector’s increasing focus on greener practices.
Iain Menneer, CEO of SageTech Medical, said:
“We are thrilled to be partnering with Dräger Switzerland. This distribution agreement comes at a crucial time when healthcare providers are prioritising environmental sustainability. Anaesthetic gases, while essential in medicine, are also potent greenhouse gases with a considerable carbon footprint. The SID-Dock offers a practical solution, enabling hospitals and clinics to capture these gases, reduce emissions, and adhere to environmental regulations.”
The collaboration with Dräger Switzerland strengthens SageTech Medical’s European expansion efforts by leveraging Dräger’s extensive market expertise and established infrastructure.
Thomas Kunz, Head of Sales & Service Medical, Dräger Schweiz AG, added:
“We are excited to be the exclusive representative of SageTech in Switzerland. This partnership represents an important step towards sustainability and green anaesthesia. By adding SageTech’s innovative solutions to our portfolio, we are addressing the current trends and are confident that this will enable us to meet the requirements of the market and our customers even better.”
By introducing an advanced gas capture and recycling solution, SageTech Medical is significantly reducing the environmental impact of anaesthetic gases. Additionally, its innovative circular economy approach minimises the carbon footprint linked to the production of virgin anaesthetic agents. |
The market has zero interest in either of them.
TEK is 10p today vs NAV of 25P
EMV is 50p today vs NAV of £1.50+
Merge the 2 and save £500k+ on costs might be a start! |
Last week from Ventive.
Assume they finally have a home heat pump to sell!?
Looking forward to joining our European partners this week! First stop Lille - to showcase the Plus Energy Building, a hashtag#retrofit featuring hashtag#VentiveHome - our all-in-one hashtag#heatpump |
When is this share going to do something?? |
PDSB corporate presentation https://www.sec.gov/Archives/edgar/data/1472091/000114036125003082/ef20042909_ex99-2.htm |
PDSB have announced phase 3 trials to start the quarter. Now where is the detail on funding?!? |
Not a chance. Looks like more capital required in portfolio companies. Discount to NAV thoroughly deserved here. |
Will someone please bid for this company and then dismantles it by selling all its component parts at a significant profit? |
Needs more money though and that's the problem here and elsewhere. |
Strong growth at ProAxsis, lowered costs - and fund raise. The growth looks excellent - ProAxsis is valued at £8m, over half of the NAV of EMV alone. |
This is looking super interesting here. I'm tempted.. |
On a slightly more positive note!
Results due and banging the drum for partnerships.
Can't see the point if they didn't have a good story to tell?
Charles Swindell, PhD
Leading Life Science Product Commercialization
1h
Excited to share the Glycotest, Inc. story at the SPRING 2025 DIGITAL VENTURE Forum investor conference March 17-21, 2025. Looking forward to connecting for one-on-one meetings (hxxps://ventureforum.net/). #InvestorConference #DigitalVentureForum |
PDSB isn't helping. I'd have expected the financing of p3 to have been announced already |
There was the Qbot fundraising on 31/12/24 and the Wanda Health Fundraising on 9/12/24 so it’s 1 month without news. But I agree the share price performance is currently disappointing,particularly in view of Simon Thompson article on 3rd December which concluded:
“ Assuming full subscription of both the retail offer and subscription, EMV will have 27.36mn shares in issue, implying the directly held portfolio is worth around 152p per share, or more than three times the current share price.
So, having outlined a strong investment case when I last suggested buying the shares, at 51.5p (‘A venture capital company on a huge discount’, 1 October 2024), I would recommend participating in the retail offer. Buy.” |
2 months with zero news doesn't help. |
It just the low volumes that are causing this volatility. Clearly a fall of 5.7% on volume of 12000 from 4 trades is ridiculous. The value is there but is not currently reflected in the share price. It could be argued this creates a buying opportunity. |
Got to love this share! |
We really need PDSB to give p3 financing details |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
